PAP
VTGN icon

Persistent Asset Partners’s VistaGen Therapeutics VTGN Stock Holding History

Persistent Asset Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,612
Closed -$16.1K – 920
2026
Q1 		$15.2K Hold
26,612
– – 0.01% 281
2025
Q4 		$17.6K Sell
26,612
-48,707
-65% -$176K 0.01% 316
2025
Q3 		$267K Sell
75,319
-11,500
-13% -$34.4K 0.18% 117
2025
Q2 		$174K Sell
86,819
-34,832
-29% -$79.1K 0.13% 120
2025
Q1 		$304K Hold
121,651
– – 0.26% 81
2024
Q4 		$352K Buy
+121,651
New +$342K 0.29% 75

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Persistent Asset Partners's VTGN Position: Q2 2026 in Review

Persistent Asset Partners sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 26,612 shares — an estimated $16.1K sold.

Persistent Asset Partners first reported a position in VTGN in Q4 2024 and held it in 6 quarters. The position peaked at $352K in Q4 2024. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Persistent Asset Partners reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 26,612 VistaGen Therapeutics shares in Q2 2026, an estimated $16.1K.
  • Persistent Asset Partners first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 6 quarters.
  • Persistent Asset Partners's VistaGen Therapeutics position peaked at $352K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.